%0 Journal Article
%A Hegenbart, Ute
%A Bochtler, Tilmann
%A Benner, Axel
%A Becker, Natalia
%A Kimmich, Christoph
%A Kristen, Arnt V
%A Beimler, Jörg
%A Hund, Ernst
%A Zorn, Markus
%A Freiberger, Anja
%A Gawlik, Marianne
%A Goldschmidt, Hartmut
%A Hose, Dirk
%A Jauch, Anna
%A Ho, Anthony D
%A Schönland, Stefan O
%T Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
%J Haematologica
%V 102
%N 8
%@ 1592-8721
%C Pavia
%I Ferrata Storti Foundation
%M DKFZ-2017-04074
%P 1424 - 1431
%D 2017
%X Chemotherapy in light chain amyloidosis aims to normalize the involved free light chain in serum, which leads to an improvement, or at least stabilization of organ function in most responding patients. We performed a prospective single center phase 2 trial with 50 untreated patients not eligible for high-dose treatment. The treatment schedule comprised 6 cycles of oral lenalidomide, melphalan and dexamethasone every 4 weeks. After 6 months, complete remission was achieved in 9 patients (18
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28522573
%2 pmc:PMC5541875
%R 10.3324/haematol.2016.163246
%U https://inrepo02.dkfz.de/record/128052